PMID- 29577093
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220316
IS  - 2391-5463 (Print)
IS  - 2391-5463 (Electronic)
VI  - 13
DP  - 2018
TI  - Evaluation of a Neurokinin-1 Antagonist in Preventing Multiple-day 
      Cisplatin-induced Nausea and Vomiting.
PG  - 29-34
LID - 10.1515/med-2018-0005 [doi]
AB  - OBJECTIVE: To perform a prospective non-randomized comparison of the 
      effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment 
      with the standard multiple-day cisplatin regimen for the prevention of 
      cisplatin-induced nausea and vomiting (CINV). METHODS: Patients being 
      administered 3-day cisplatin-based chemotherapy (25 mg/m(2)/d) who had never 
      received aprepitant were given either the standard regimen (tropisetron and 
      dexamethasone) or the aprepitant regimen (aprepitant plus tropisetron and 
      dexamethasone). The primary endpoint was the complete response (CR) in the 
      overall phase (OP, 0-120 h) between the combined aprepitant triple regimen group 
      and the standard group. Secondary endpoints were the CR in the acute phase (AP, 
      0-24 h) and delay phase (DP, 25-120 h) between the two groups. The first time of 
      vomiting was also compared by Kaplan-Meier curves. The impact of CINV on the 
      quality of life was assessed by the Functional Living Index-Emesis (FLIE). 
      Aprepitant-related adverse effects (AEs) were also recorded. RESULTS: A CR was 
      achieved by 80.0% in the aprepitant group compared with 56.0% in the standard 
      group during the OP (P =0.018)as well as during the DP. However, during the AP, 
      the aprepitant and standard therapy groups achieved identical CR rates (98.0%, P 
      =1.000). A longer time to first emesis was documented for the aprepitant group 
      than for the standard group. No effect of CINV on quality of life as assessed by 
      FLIE was reported by 44.7% of aprepitant therapy patients and 24.0% of standard 
      therapy patients (P=0.035). The main aprepitant-related AEs were fatigue and 
      constipation, but there was no significant difference between groups. CONCLUSION: 
      Combined aprepitant therapy is recommended for the prevention of multiple-day 
      CINV because of its improved CINV control rate and safety.
FAU - Li, Quanfu
AU  - Li Q
AD  - Department of Medical Oncology, Ordos Central Hospital, 017000Ordos, Mongolia, 
      China.
FAU - Wang, Wenjuan
AU  - Wang W
AD  - Department of Medical Oncology, Ordos Central Hospital, 017000Ordos, Mongolia, 
      China.
FAU - Chen, Gang
AU  - Chen G
AD  - Department of Medical Oncology, Ordos Central Hospital, 017000Ordos, Mongolia, 
      China.
FAU - Deng, Shuqin
AU  - Deng S
AD  - Department of Medical Oncology, Ordos Central Hospital, 017000Ordos, Mongolia, 
      China.
FAU - Jiang, Caihong
AU  - Jiang C
AD  - Department of Medical Oncology, Ordos Central Hospital, 017000Ordos, Mongolia, 
      China.
FAU - Chen, Feng
AU  - Chen F
AD  - Department of Medical Oncology, Ordos Central Hospital, 017000Ordos, Mongolia, 
      China.
FAU - Zhao, Jun
AU  - Zhao J
AD  - Department of Medical Oncology, Ordos Central Hospital, 017000Ordos, Mongolia, 
      China.
FAU - Li, Hui
AU  - Li H
AD  - Department of Medical Oncology, Ordos Central Hospital, 017000Ordos, Mongolia, 
      China.
FAU - Bai, Xiaojun
AU  - Bai X
AD  - Department of Medical Oncology, Ordos Central Hospital, 017000Ordos, Mongolia, 
      China.
FAU - Hu, Yuliang
AU  - Hu Y
AD  - Department of Medical Oncology, Ordos Central Hospital, 017000Ordos, Mongolia, 
      China.
FAU - Da, Lenggaowa
AU  - Da L
AD  - Department of Medical Oncology, Ordos Central Hospital, 017000Ordos, Mongolia, 
      China.
FAU - Wu, Yungaowa
AU  - Wu Y
AD  - Department of Medical Oncology, Ordos Central Hospital, 017000Ordos, Mongolia, 
      China.
FAU - Jin, Gaowa
AU  - Jin G
AD  - Ordos Central Hospital, Department of Medical Oncology, 23th Yinjihuoluo Western 
      Road, Ordos, 017000, China.
LA  - eng
PT  - Journal Article
DEP - 20180315
PL  - Poland
TA  - Open Med (Wars)
JT  - Open medicine (Warsaw, Poland)
JID - 101672167
PMC - PMC5851005
OTO - NOTNLM
OT  - Aprepitant
OT  - CINV
OT  - Multiple-day cisplatin chemotherapy
COIS- Conflict of interest statement: The authors confirm that this article content has 
      no conflict of interests.
EDAT- 2018/03/27 06:00
MHDA- 2018/03/27 06:01
PMCR- 2018/03/15
CRDT- 2018/03/27 06:00
PHST- 2017/09/20 00:00 [received]
PHST- 2017/12/07 00:00 [accepted]
PHST- 2018/03/27 06:00 [entrez]
PHST- 2018/03/27 06:00 [pubmed]
PHST- 2018/03/27 06:01 [medline]
PHST- 2018/03/15 00:00 [pmc-release]
AID - med-2018-0005 [pii]
AID - 10.1515/med-2018-0005 [doi]
PST - epublish
SO  - Open Med (Wars). 2018 Mar 15;13:29-34. doi: 10.1515/med-2018-0005. eCollection 
      2018.